Abemacyclib is a unique representative of the class of CDK4/6 inhibitors in the treatment of HR+/HER2- metastatic breast cancer

Autor:	A.A. Prosvirnov Prosvirnov, E.V. Lubennikova Lubennikova, I.V. Kolyadina Kolyadina, K.S. Grechukhina Grechukhina, K.A. Vorontsova Vorontsova, T.M. Kuko Kuko, Perinatology n.a. Acad. V.I. Kulakov, Moscow, Russia, L.G. Zhukova Zhukova, I.P. Ganshina Ganshina
Rok vydání:	2021
Předmět:	Oncology medicine.medical_specialty business.industry Internal medicine Medicine business medicine.disease Class (biology) Metastatic breast cancer
Zdroj:	Pharmateca. :15-27
ISSN:	2414-9128
DOI:	10.18565/pharmateca.2021.7.15-27
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::9d8bae790d1f7715fc16ec03f9edef3a https://doi.org/10.18565/pharmateca.2021.7.15-27 Zobrazit plný text záznamu